Fig. 1:

Study design

LLTs, lipid-lowering therapies; MTD, maximum tolerated dose

^aLomitapide dose reduction permitted where dose modification rules applied. Subsequent re-escalation allowed if ≤ MTD (determined during efficacy phase)

^bDerived baseline was calculated from average value of Visit 2 and Visit Visit 3 at Phase 3 study